SBRT boost radiation therapy in intermediate- and high-risk prostate cancer

Recently we have seen evidence of improved cancer control in high-risk patients treated with external beam radiotherapy with a brachytherapy boost to the prostate. This has been demonstrated with both HDR brachytherapy boost and with LDR brachytherapy boost. … READ MORE …

Salvage SBRT for local recurrence after first-line (primary) radiation therapy

This is the second part of a two-part commentary. In the first part, we looked at studies that identified the site of failure after primary radiation treatment, … READ MORE …

SBRT has equivalent toxicity when given with 5 and 12 treatments

Data reported at the recent Genitourinary Cancers Symposium have shown that the toxicities associated with stereotactic body radiation therapy (SBRT) are acceptable and similar whether the radiation is give as 5 or 12 doses. … READ MORE …

Nine-year outcomes after treatment with SBRT

Katz and Kang will present their 9-year outcomes on 515 patients treated by stereotactic body radiation therapy (SBRT) at the Genitourinary Cancers Symposium tomorrow … READ MORE …

SBRT for oligometastatic recurrence

Although the theory of the existence of a temporarily stable oligometastatic stage in prostate cancer is more than 20 years old, it remains unknown whether there is any benefit to pursuing curative or progression-delaying radiation (or indeed other forms of targeted treatment) if there are only a few metastases detected at recurrence. … READ MORE …

Longer time between treatments reduces SBRT rectal toxicity

There are many details of stereotactic body radiation therapy (SBRT) that may be optimized over the coming years. Among them is the optimum treatment schedule — i.e., how far apart should the treatments be spaced? … READ MORE …

SBRT for high-risk prostate cancer

Treatments for high-risk prostate cancer are limited. Surgery is usually considered a poor option if the cancer has already escaped the prostate capsule (stage T3/4). External beam radiation is often given with hormone therapy for high grade cancers, or with a brachytherapy boost. … READ MORE …

Can salvage radiation therapy be safely and effectively completed in less time?

Salvage or adjuvant external beam radiation therapy for prostate cancer is usually a protracted affair, more so since we learned that a total dose of about 64 Gy to 70 Gy was needed to be effective in the salvage setting. … READ MORE …

SBRT as focal treatment for isolated, nodal metastasis

A group of Italian researchers has reported preliminary clinical experience of the use of stereotactic body radiation therapy (SBRT), using CyberKnife technology, in the treatment of isolated, nodal metastases as a consequence of prostate cancer. … READ MORE …

7-year outcomes data after treatment with SBRT

A new article in Frontiers in Oncology now provides us with data from the median 6-year follow-up of > 450 men with prostate cancer treated with stereotactic body radiation therapy (SBRT) using the CyberKnife technology. … READ MORE …

Is SBRT more toxic than IMRT in treatment of localized prostate cancer?

A new paper, published online today in the Journal of Clinical Oncology, suggests that stereotactic body radiation therapy (SBRT, commonly delivered using the CyberKnife system) has a higher risk for genitourinary (GU) toxicity than intensity-modulated radiation therapy (IMRT). … READ MORE …

Medium-term outcome data on CyberKnife SBRT for localized prostate cancer

A paper in the May issue of the journal Radiation Oncology has provided 6-year outcome data (including quality of life and complications of treatment) after the use of stereotactic body radiation therapy (SBRT) using the CyberKnife system (from the Flushing Radiation Oncology group in Flushing, New York). … READ MORE …

CyberKnife radiation in treatment of intermediate-risk prostate cancer

A new paper in the journal Radiation Oncology provides data on a series of 41 men treated with stereotactic body radiation therapy for intermediate-risk prostate cancer. … READ MORE …

SBRT in men with intermediate-risk, localized prostate cancer

Data reported by Meier et al. and presented at the recent annual meeting of the American Society for Radiation Oncology (ASTRO) provide some early guidance on the efficacy and safety of sterotactic body radiation therapy (SBRT) in treatment of men with intermediate-risk, localized prostate cancer. … READ MORE …

Data from large, retrospective study shows 5-year efficacy for SBRT in localized prostate cancer

Data from a large, retrospective, multi-center study of stereotactic body radiation therapy (SBRT) with CyberKnife technology in the treatment of men with localized prostate cancer were presented on Wednesday afternoon at the annual meeting of the American Society for Radiation Oncology (ASTRO). … READ MORE …